faradaypharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
# Squarespace Robots Txt User-agent: AdsBot-Google Disallow: /config Disallow: /search Disallow: /account$ Disallow: /account/ Disallow: /commerce/digital-download/ Disallow: /api/ Allow: /api/ui-extensions/ Disallow: /static/ Disallow:/*?author=* Disallow:/*&author=* Disallow:/*?tag=* Disallow:/*&tag=* Disallow:/*?month=* Disallow:/*&month=* Disallow:/*?view=* Disallow:/*&view=* Disallow:/*?format=json Disallow:/*&format=json Disallow:/*?format=page-context Disallow:/*&format=page-context Disallow:/*?format=main-content Disallow:/*&format=main-content Disallow:/*?format=json-pretty Disallow:/*&format=json-pretty Disallow:/*?format=ical Disallow:/*&format=ical Disallow:/*?reversePaginate=* Disallow:/*&reversePaginate=* User-agent: AdsBot-Google-Mobile Disallow: /config Disallow: /search Disallow: /account$ Disallow: /account/ Disallow: /commerce/digital-download/ Disallow: /api/ Allow: /api/ui-extensions/ Disallow: /static/ Disallow:/*?author=* Disallow:/*&author=* Disallow:/*?tag=* | ||
Meta Tags
| Title | Faraday |
| Description | Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents. These therapeutic agents have potential applications for treatment of critical care |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 198.185.159.145 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
faradaypharma.com Valuation
|
US$6,214,017
Last updated: 2023-05-13 03:56:29
faradaypharma.com has Semrush global rank of 1,703,295. faradaypharma.com has an estimated worth of US$ 6,214,017, based on its estimated Ads revenue. faradaypharma.com receives approximately 717,002 unique visitors each day. Its web server is located in United States, with IP address 198.185.159.145. According to SiteAdvisor, faradaypharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$6,214,017 |
| Daily Ads Revenue | US$5,737 |
| Monthly Ads Revenue | US$172,081 |
| Yearly Ads Revenue | US$2,064,966 |
| Daily Unique Visitors | 47,801 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| faradaypharma.com. | A | 599 | IP: 198.185.159.145 |
| faradaypharma.com. | A | 599 | IP: 198.185.159.144 |
| faradaypharma.com. | A | 599 | IP: 198.49.23.145 |
| faradaypharma.com. | A | 599 | IP: 198.49.23.144 |
| faradaypharma.com. | NS | 3600 | NS Record: ns16.domaincontrol.com. |
| faradaypharma.com. | NS | 3600 | NS Record: ns15.domaincontrol.com. |
| faradaypharma.com. | MX | 3600 | MX Record: 0 faradaypharma.in.tmes.trendmicro.com. |
| faradaypharma.com. | TXT | 3600 | TXT Record: tmes=6e5d376334d8ad25d258938bd3194421 |
| faradaypharma.com. | TXT | 3600 | TXT Record: MS=FF4287CA0E4FE2F9E3A29DFC773302FB8447E5B7 |
| faradaypharma.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com include:spf.tmes.trendmicro.com -all |
HtmlToTextCheckTime:2023-05-13 03:56:29
| About Company Leadership Investors Science Overview FDY-5301 News Publications Careers Contact Our mission is to improve the quality of life for patients experiencing a potentially life changing critical illness. RECENT NEWS Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction SEATTLE, May 10, 2022 – Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular (CV) death and heart failure in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous intervention (PCI). The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration. Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack December |
HTTP Headers
HTTP/1.1 301 Moved Permanently Age: 300862 Date: Fri, 17 Dec 2021 04:24:07 GMT Location: https://faradaypharma.com/ Server: Squarespace Set-Cookie: crumb=BQpjKfYFxduKMTEwMDg1MDkxOGNhZmQ0OWRmNTVhZmZkOWVmMmEy;Path=/ X-Contextid: PnRpuivt/Ioh21UhS HTTP/2 200 accept-ranges: bytes age: 300578 content-type: text/html;charset=utf-8 date: Fri, 17 Dec 2021 04:28:50 GMT etag: W/"f346543575035646584c0d5af08e504f" expires: Thu, 01 Jan 1970 00:00:00 GMT last-modified: Fri, 17 Dec 2021 04:28:50 GMT server: Squarespace set-cookie: crumb=BQaZoaq1ZtipN2Y1NjEyMWUwN2NmMjM1YTMyN2ZhMzY1MDY2Yjlj;Path=/ strict-transport-security: max-age=0 vary: Accept-Encoding x-content-type-options: nosniff x-contextid: GSPHmO41/tvDl9HDq content-length: 10903 |
faradaypharma.com Whois Information
Domain Name: FARADAYPHARMA.COM Registry Domain ID: 1860477748_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-05-27T17:12:27Z Creation Date: 2014-05-27T23:18:23Z Registry Expiry Date: 2022-05-27T23:18:23Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS15.DOMAINCONTROL.COM Name Server: NS16.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-24T08:14:58Z <<< |